TSH Biopharm Corporation Limited

8432

TW0008432006

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
60.3 ^TWD	+2.20%		+10.24%	+19.88%

Mar. 11	TSH Biopharm Corporation Limited Announces Directorate Changes on April 1, 2024	CI
Mar. 11	TSH Biopharm Corporation Limited Appoints Jung-Liang Kao as CFO on April 1, 2024	CI

Tsh Biopharm Corporation Limited Announces the Change of Audit Committee Members

May 25, 2023 at 04:26 am EDT

TSH Biopharm Corporation Limited announced Name of the previous position holder: 1)Chih-Li Wang (2)Rwei-Syun Chen (3)Yaw-Bin Huang Resume of the previous position holder: (1)Chih-Li Wang:Partner CPA of Moores Rowland CPAs (2)Rwei-Syun Chen:Independent Director of Welgene Biotech Co. Ltd. (3)Yaw-Bin Huang:Dean of School of Pharmacy, Kaohsiung Medical University Name of the new position holder: (1)Te-Yu Chou (2)Rwei-Syun Chen (3)Yaw-Bin Huang Resume of the new position holder: 1)Te-Yu Chou:Independent Director of Taiwan Cooperative Bank (2)Rwei-Syun Chen:Independent Director of Welgene Biotech Co. Ltd.
(3)Yaw-Bin Huang:Dean of School of Pharmacy, Kaohsiung Medical University.

Latest news about TSH Biopharm Corporation Limited

TSH Biopharm Corporation Limited Announces Directorate Changes on April 1, 2024	Mar. 11	CI
TSH Biopharm Corporation Limited Appoints Jung-Liang Kao as CFO on April 1, 2024	Mar. 11	CI
TSH Biopharm Corporation Limited agreed to acquire an unknown stake in TOP Pharm. Medicalware Company Limited from Gu An Engineering Consultants Co., Ltd., Kao Tuan International Consulting Co., Ltd., ANIMATO INTERNATIONAL COMPANY, Shen Feng Co., Ltd. and others for TWD 257.1 million.	Mar. 10	CI
TSH Biopharm Corporation Limited agreed to acquire 51% stake in TOP Biological Technology Company Limited from Shen Feng Co., Ltd., Gu An Engineering Consultants Co., Ltd., Kao Tuan International Consulting Co., Ltd. ANIMATO INTERNATIONAL COMPANY and others for TWD 44.3 million.	Mar. 10	CI
TSH Biopharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
TSH Biopharm Corporation Limited Announces the Change of Financial Officer, Effective on January 1, 2024	Dec. 14	CI
TSH Biopharm Corporation Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
TSH Biopharm Corporation Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Tsh Biopharm Corporation Limited Announces the Change of Audit Committee Members	23-05-25	CI
Tsh Biopharm Corporation Limited Announces Dividend for the Year 2022, Payable on July 14, 2023	23-05-25	CI
TSH Biopharm Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
TSH Biopharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-10	CI
TSH Biopharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-10	CI
TSH Biopharm Corporation Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-02	CI
TSH Biopharm Corporation Limited Announces Board Appointments	22-08-04	CI
TSH Biopharm Corporation Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-03	CI
TSH Biopharm Corporation Limited Appoints Yaw-Bin, Huang as Audit Committee Member	22-05-24	CI
TSH Biopharm Corporation Limited Announces Cash Dividends, Payable on July 8, 2022	22-05-24	CI
TSH Biopharm Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-04	CI
TSH Biopharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-03	CI
TSH Biopharm Corporation Limited Announces Resignation of Yi-Min Wang from Audit Committee and Remuneration Committee	22-02-21	CI
TSH Biopharm Corporation Limited Announces Resignation of Yi-Min Wang as Company's Independent Director	22-02-21	CI
TSH Biopharm Corporation Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-02	CI
TFDA Approves TSH Biopharm Corporation Limited's New Combo New Drug Reta19	21-10-20	CI
TSH Biopharm Corporation Limited Announces Cash Dividend, Payable on Oct. 08, 2021	21-08-20	CI

Chart TSH Biopharm Corporation Limited

Duration

Period

More charts

Company Profile

Tsh biopham corporation ltd. is a Taiwan-based company principally engaged in the manufacturing and distribution of medical preparations. The Company primarily provides medicines for cardiovascular, including Amtrel, Rytmonorm, Licodin, Isormol and ISOPTIN SR; medicines for intestines and stomach, including MOPRIDE, Catilon, Gastro-Timelet and Ribarin, and medicines for central nervous, including Aleviatin, Lonine and Lacoxa SR. The Company distributes its products mainly in domestic markets.

Sector

Pharmaceuticals

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TSH BIOPHARM CORPORATION LIMITED	+19.88%	70.98M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B